The patient journey of head neck cancer from primary care to diagnosis – A retrospective cohort study in the Netherlands
Cancer Epidemiology · 2025
DOI: 10.1016/j.canep.2025.102865 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Cancer Epidemiology, 2025. Verfasst von Naomi Reimes und 7 weiteren Autor:innen. Beteiligte Einrichtung: PHARMO Institute for Drug Outcomes Research, Utrecht, the Netherlands. Electronic address: naomi.reimes@pharmo.com. Hauptthemen laut MEDLINE: Head and Neck Neoplasms, Primary Health Care. Die Arbeit nennt 44 Literaturangaben. Gefördert von: MSD, Merck Sharp & Dohme.
Abstract (Originalsprache)
OBJECTIVE: There are currently no data available on the referral landscape of head and neck cancer (HNC) patients from first visit to a general practitioner (GP) to diagnosis in the Netherlands. Since primary care is a key setting to reduce time to diagnosis (TTD), this study aimed to describe the healthcare pathway of HNC patients from first GP visit to diagnosis. STUDY DESIGN: This study was a population-based case-control study among patients with HNC matched to a non-HNC control group. SETTING: The data collection period was between 2013 and 2020, the setting was in the Netherlands. METHODS: Patient and tumor characteristics were assessed at index date. The healthcare pathway between start date and index date was assessed, as well as TTD for cases, which was stratified by patient and tumor characteristics. RESULTS: The final study population consisted of 9565 persons, of which 1913 HNC patients and 7652 matched non-HNC controls. Cases were most often male (67 %), median age was 66 years. HNC patients had more often a smoking and drinking history compared to controls (p < 0.0001). Cases had more GP visits, received more medication, were ordered more laboratory tests and had more referrals to a specialist, compared to controls (all p < 0.05). The overall mean (±standard deviation) TTD was 43.0 (±34.3) weeks, and was affected by gender, tumor location, and number of GP visits. CONCLUSION: This is the first study that reported the demographics and healthcare use from first GP visit to diagnosis in the Netherlands. Future research should focus on identifying opportunities for earlier diagnosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- PHARMO Institute for Drug Outcomes Research, Utrecht, the Netherlands. Electronic address: naomi.reimes@pharmo.com.
- University of Exeter, College House, St. Luke's Campus, Exeter, UK.
- MSD, Haarlem, the Netherlands.
- PHARMO Institute for Drug Outcomes Research, Utrecht, the Netherlands.
- Department of Pathology, University Medical Center Utrecht, Utrecht, the Netherlands; Department of Pathology, University Medical Center Groningen, Groningen, the Netherlands.
- Department of Otolaryngology and Head and Neck Surgery, Radboud University Medical Center, Nijmegen, the Netherlands.
Förderung
- MSD
- Merck Sharp & Dohme
Zitieren
APA
Reimes, N., Bailey, S. E., Post, J. B., Kuiper, J. G., van Nieuwenhuizen, B. P., Overbeek, J. A., Willems, S. M., & Takes, R. P. (2025). The patient journey of head neck cancer from primary care to diagnosis – A retrospective cohort study in the Netherlands. Cancer Epidemiology. https://doi.org/10.1016/j.canep.2025.102865
Vancouver
Reimes N, Bailey SE, Post JB, Kuiper JG, van Nieuwenhuizen BP, Overbeek JA, et al. The patient journey of head neck cancer from primary care to diagnosis – A retrospective cohort study in the Netherlands. Cancer Epidemiology. 2025. doi:10.1016/j.canep.2025.102865
BibTeX
@article{Reimes2025,
author = {Reimes, Naomi and Bailey, Sarah Er and Post, Jasmin B and Kuiper, Josephina G and van Nieuwenhuizen, Benjamin P and Overbeek, Jetty A and Willems, Stefan M and Takes, Robert P},
title = {The patient journey of head neck cancer from primary care to diagnosis – A retrospective cohort study in the Netherlands},
journal = {Cancer Epidemiology},
year = {2025},
doi = {10.1016/j.canep.2025.102865}
}
EUVIMED